SCHEDULE 13G: Great Point Partners and Affiliates Disclose 5.12% Stake in Zura Bio Ltd

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl, have jointly disclosed a beneficial ownership of 5.12% in Zura Bio Ltd's Class A Ordinary Shares.

Summary

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl have filed a Schedule 13G, indicating a collective beneficial ownership of 3,170,194 Class A Ordinary Shares of Zura Bio Ltd.
• This ownership represents 5.12% of Zura Bio Ltd's Class A Ordinary Shares outstanding, based on 61,874,998 shares reported by the Issuer in its Form 10-Q filed on May 8, 2025.
• The reporting persons, including Great Point Partners as an investment manager and Dr. Jay and Ms. Nordahl as Senior Managing Member and Managing Director, respectively, hold shared voting and dispositive power over these shares.
• The shares are held through Biomedical Value Fund, L.P. (2,124,030 shares) and Biomedical Offshore Value Fund, Ltd. (1,046,164 shares), for which Great Point is the investment manager.
• The filing states that the securities were not acquired and are not held for the purpose of changing or influencing the control of Zura Bio Ltd.

Sentiment

Score: 7

Explanation: The filing indicates a significant investment by a reputable institutional investor, which is generally a positive signal for the company, implying confidence in its value. The purpose is passive investment, not control, which is neutral.

Positives

• The disclosure of a significant stake by an institutional investor like Great Point Partners, LLC, can be viewed as a vote of confidence in Zura Bio Ltd's future prospects.
• The investment by a specialized healthcare investment firm suggests a belief in the value and potential of Zura Bio Ltd's assets or pipeline.

Risks

• The reporting persons disclaim beneficial ownership of the shares except to the extent of their respective pecuniary interests, which is a standard disclaimer but highlights that their control is limited to their financial stake.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Zura Bio Ltd.

Industry Context

This filing indicates an investment by a private equity firm specializing in healthcare, suggesting a strategic interest in the biotechnology or pharmaceutical sector where Zura Bio Ltd operates. Such investments are common in the industry as firms seek to capitalize on growth opportunities in innovative healthcare companies.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor could potentially increase investor confidence and positively influence share price.
• Company Management: Awareness of a new significant shareholder may influence strategic decisions, though the filing states the investment is not for control.

Key Dates

Keywords

Zura Bio Ltd, Great Point Partners, Schedule 13G, Beneficial Ownership, Class A Ordinary Shares, Institutional Investor, SEC Filing, Biomedical Value Fund, Biomedical Offshore Value Fund, Healthcare Investment